Rigel Pharmaceuticals in-licensed Veppanu, a drug for the treatment of certain breast cancer patient

Rigel's Q2 beat big ($78.7M revenue, $0.88 EPS), driven by TAVALISSE, but GAVRETO's year-over-year d

Rigel Pharmaceuticals, Inc. (RIGL) Q2 2026 Earnings Call Transcript

Rigel Pharmaceuticals NASDAQ: RIGL reported second-quarter 2026 total revenue of $78.7 million and n

Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $0.88 per share, missing the Zacks

Gainers Bluejay Diagnostics (NASDAQ:BJDX) stock moved upwards by 42.0% to $1.42 during Tuesday'

Second quarter 2026 total revenues of $78.7 million, including net product sales of $67.0 million an

SOUTH SAN FRANCISCO, Calif., July 28, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL

SOUTH SAN FRANCISCO, Calif., July 7, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nas

Dr. Hannah has decades of oncology drug development experience and has served on Rigel's Board of Di

Rigel Pharmaceuticals trades at an attractive valuation after a 35% pullback, with a market cap just

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hemat

SOUTH SAN FRANCISCO, Calif., June 16, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL

SOUTH SAN FRANCISCO, Calif., May 27, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL)

Oral presentation at ASCO Annual Meeting to feature final data from the Phase 3 AcceleRET-Lung clini

SOUTH SAN FRANCISCO, Calif., May 14, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL)

Arvinas Inc (NASDAQ:ARVN) reported Q1 losses of 90 cents/share, missed analyst estimates. Rigel Phar

Rigel Pharmaceuticals, Inc. (RIGL) M&A Call Transcript

Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) stock is trading higher on Tuesday as the company is enteri

Rigel Pharmaceuticals stock jumps after signing a VEPPANU licensing deal with Arvinas and Pfizer fol

Arvinas, Inc. (NASDAQ:ARVN), a biotechnology company creating a new class of drugs based on targeted

VEPPANU has a novel mechanism of action, is the first and only FDA-approved PROTAC and has the poten

Rigel Pharmaceuticals, Inc. (RIGL) Q1 2026 Earnings Call Transcript

Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $0.44 per share, missing the Zacks

First quarter 2026 total revenues of $58.8 million, including net product sales of $54.9 million and

U.S. stocks up on Wednesday with NASDAQ gaining 0.85%. ISM services PMI rose to 56.1. VCI Global Ltd

Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51

Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings

Companies Reporting Before The Bell • Toyota Motor (NYSE:TM) is estimated to report earnings for it

Companies Reporting Before The Bell • Cohen & Co (AMEX:COHN) is likely to report earnings for i

Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnin

Gainers FedNat Holding Company (NASDAQ: FNHC) shares climbed 107.7% to close at $0.3395 on Tuesda

Gainers Fujian Blue Hat Interactive Entertainment Technology Ltd. (NASDAQ: BHAT) shares jumped 2

Gainers Advent Technologies Holdings, Inc. (NYSE: ADN) shares surged 244% to close at $3.99 on Th

  On Wednesday, 73 stocks hit new 52-week lows.

  Companies Reporting Before The Bell • Kiniksa Pharmaceuticals (NASDAQ:KNSA) is projected to repo

  During Friday's session, 445 companies made new 52-week lows.

  Companies Reporting Before The Bell • Thomson Reuters (NYSE:TRI) is expected to report quarterly

  Companies Reporting Before The Bell • Myriad Genetics (NASDAQ:MYGN) is likely to report earnings